Safety Study of Stemchymal® in Acute Liver Failure (ALF)
Primary Purpose
Stem Cells, Adult Stem Cells, Acute Liver Failure
Status
Withdrawn
Phase
Phase 1
Locations
Taiwan
Study Type
Interventional
Intervention
Stemchymal®
Sponsored by
About this trial
This is an interventional treatment trial for Stem Cells
Eligibility Criteria
Inclusion Criteria:
- ALF or ACLF patients.
- Subjects are between 20 and 70 years of age.
- MELD scores meet 17 ≤ MELD ≤ 26.
- Subjects who had completed signing informed consent.
Exclusion Criteria:
- Subjects who had been enrolled in any other cell therapy within six months.
- Females with a positive pregnancy test result.
- Subjects have contraindication for liver transplantation.
- Subjects with psychiatric illnesses.
- Subjects who are diagnosed as active tuberculosis (TB).
- Subjects with immunological disorders (e.g. autoimmune hepatitis) or using immunosuppressive drugs (e.g. steroid for immunosuppression) within six months prior to screening visit.
- Subjects with unstable illnesses or contraindication for this clinical trial according to investigator's judgment.
Sites / Locations
- Taipei Veterans General Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Stemchymal®
Arm Description
Biological: Stemchymal® ALF/ ACLF patients will receive low (0.5 x 10^6 cells/kg) or high (2 x 10^6 cells/kg) dose of Stemchymal® through intravenous infusion
Outcomes
Primary Outcome Measures
The incidence of adverse events (AEs) and suspected unexpected serious adverse reaction (SUSAR)
Secondary Outcome Measures
Full Information
NCT ID
NCT03629015
First Posted
July 30, 2018
Last Updated
October 26, 2022
Sponsor
Steminent Biotherapeutics Inc.
Collaborators
Taipei Veterans General Hospital, Taiwan
1. Study Identification
Unique Protocol Identification Number
NCT03629015
Brief Title
Safety Study of Stemchymal® in Acute Liver Failure
Acronym
ALF
Official Title
The Safety Study of Stemchymal® (Allogeneic Adipose-Derived Mesenchymal Stem Cells) Treating on Acute Liver Failure - An Open-Label, Single-Center Phase I Trial
Study Type
Interventional
2. Study Status
Record Verification Date
October 2022
Overall Recruitment Status
Withdrawn
Why Stopped
Corporate strategic consideration
Study Start Date
October 1, 2018 (Anticipated)
Primary Completion Date
May 18, 2020 (Actual)
Study Completion Date
May 18, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Steminent Biotherapeutics Inc.
Collaborators
Taipei Veterans General Hospital, Taiwan
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To investigate the safety of Stemchymal® via intravenous (IV) infusion in acute liver failure (ALF) and acute on chronic liver failure (ACLF) patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stem Cells, Adult Stem Cells, Acute Liver Failure, Acute-On-Chronic Liver Failure, Steminent
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Stemchymal®
Arm Type
Experimental
Arm Description
Biological: Stemchymal® ALF/ ACLF patients will receive low (0.5 x 10^6 cells/kg) or high (2 x 10^6 cells/kg) dose of Stemchymal® through intravenous infusion
Intervention Type
Biological
Intervention Name(s)
Stemchymal®
Intervention Description
ALF/ ACLF patients will receive Stemchymal® through intravenous infusion
Primary Outcome Measure Information:
Title
The incidence of adverse events (AEs) and suspected unexpected serious adverse reaction (SUSAR)
Time Frame
12 months
Other Pre-specified Outcome Measures:
Title
Changes of Model for End-Stage Liver Disease score
Time Frame
12 months
Title
Changes of Child-Pugh score
Time Frame
12 months
Title
Changes of Eastern Cooperative Oncology Group performance scale
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
ALF or ACLF patients.
Subjects are between 20 and 70 years of age.
MELD scores meet 17 ≤ MELD ≤ 26.
Subjects who had completed signing informed consent.
Exclusion Criteria:
Subjects who had been enrolled in any other cell therapy within six months.
Females with a positive pregnancy test result.
Subjects have contraindication for liver transplantation.
Subjects with psychiatric illnesses.
Subjects who are diagnosed as active tuberculosis (TB).
Subjects with immunological disorders (e.g. autoimmune hepatitis) or using immunosuppressive drugs (e.g. steroid for immunosuppression) within six months prior to screening visit.
Subjects with unstable illnesses or contraindication for this clinical trial according to investigator's judgment.
Facility Information:
Facility Name
Taipei Veterans General Hospital
City
Taipei
Country
Taiwan
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Safety Study of Stemchymal® in Acute Liver Failure
We'll reach out to this number within 24 hrs